Stifel lowered the firm’s price target on Regenxbio (RGNX) to $42 from $45 and keeps a Buy rating on the shares. The firm notes the company is moving toward pivotal readouts for RGX-202/ Duchenne muscular dystrophy and ABBV-RGX-314/ wet age related macular degeneration, with among the most comprehensive and/or largest datasets in GTx. Ahead of the 202 readout, Stifel expects additional color at the Muscular Dystrophy Association next week for further insight into safety and durability of functional benefit, offering a window into AFFINITY-DUCHENNE.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGNX:
- Regenxbio reports Q4 EPS ($1.30) vs. ($1.01) last year
- FDA review process for accelerated approval narrows, less predictable, WSJ says
- RGNX Earnings this Week: How Will it Perform?
- LEVI & KORSINSKY, LLP: RGNX DISCLOSURE TIMELINE REVEALS PATTERN OF ALLEGED INVESTOR HARM
- When a Clinical Hold Disrupts a Gene Therapy Program: What Happened to Regenxbio Stock